Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights
Most patients received standardized premedication regimens, but significant variability was observed in G-CSF use for neutropenia prophylaxis. Only 6% of patients required atropine as diarrhea premedication. Practices regarding the use of G-CSF varied across centers, reflecting evolving SmPC guidance and individual risk-based approaches to neutropenia management.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Michał Jarząb (ORCID: https://orcid.org/0000-0002-2642-9724)
- Marek Ziobro (ORCID: https://orcid.org/0000-0002-6870-9492)
- Małgorzata Pieniążek (ORCID: https://orcid.org/0000-0001-5864-0877)
- Aleksandra Łacko
- Marcin Kubeczko (ORCID: https://orcid.org/0000-0003-1877-5691)
- Manuela Las‐Jankowska (ORCID: https://orcid.org/0000-0002-3970-0368)
- Anna Polakiewicz-Gilowska (ORCID: https://orcid.org/0000-0002-2175-7067)
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Paulina Kilian-Van Miegem
Institutions
- Jagiellonian University (PL)
- Bydgoszcz University of Science and Technology (PL)
- Medical University of Warsaw (PL)
- Nicolaus Copernicus University (PL)
- University of Bydgoszcz (PL)
- Greater Poland Cancer Center (PL)
- National Institute of Oncology (HU)
- Medical University of Lodz (PL)
- Lublin Oncology Center (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1007/s00520-025-09918-4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00